home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
HaCKeRz KrOnIcKLeZ 3
/
HaCKeRz_KrOnIcKLeZ.iso
/
drugs
/
60.fr.38576
< prev
next >
Wrap
Text File
|
1996-05-06
|
13KB
|
226 lines
<ARTICLE>
Date="07/27/95"
Citation="60 FR 38576"
Group="legal"
Type="NOTICE"
Department="DEPARTMENT OF JUSTICE"
Agency="DRUG ENFORCEMENT ADMINISTRATION (DEA), JUSTICE"
Subject="Controlled Substances: Proposed Aggregate Production Quotas for 1996"
<HEADER>
------------------------------------------------------------
Drug Enforcement Administration
[DEA #134P]
Controlled Substances: Proposed Aggregate Production Quotas
for 1996
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed aggregate production quotas for 1996.
</HEADER>
------------------------------------------------------------
Drug Enforcement Administration
[DEA #134P]
Controlled Substances: Proposed Aggregate Production Quotas
for 1996
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed aggregate production quotas for 1996.
+
------------------------------------------------------------
SUMMARY: This notice proposes initial 1996 aggregate production
quotas for controlled substances in Schedules I and II of the
Controlled Substances Act.
DATES: Comments or objections should be received on or before
August 28, 1995.
ADDRESSES: Send comments or objections to the Deputy Administrator,
Drug Enforcement Administration, Washington, DC 20537, Attn:
DEA Federal Register Representative (CCR).
FOR FURTHER INFORMATION CONTACT:
Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section,
Drug Enforcement Administration, Washington, D.C. 20537, Telephone:
(202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances
Act (21 U.S.C. 826) requires that the Attorney General establish
aggregate production quotas for each basic class of controlled
substance listed in Schedules I and II. This responsibility
has been delegated to the Administrator of the DEA by Section
0.100 of Title 28 of the Code of Federal Regulations.
The Administrator, in turn, has redelegated this function
to the Deputy Administrator pursuant to sec 0.104 of Title 28
of the Code of Federal Regulations.
The quotas are to provide adequate supplies of each substance
for: (1) The estimated medical, scientific, research, and industrial
needs of the United States; (2) lawful export requirements;
and (3) the establishment and maintenance of reserve stocks.
In determining the below listed proposed 1996 aggregate production
quotas, the Deputy Administrator considered the following factors:
(1) Total actual 1994 and estimated 1995 and 1996 net disposals
of each substance by all manufacturers; (2) estimates of 1995
year-end inventories of each substance and of any substance
manufactured from it and trends in accumulation of such inventories;
and (3) projected demand as indicated by procurement quota applications
filed pursuant to sec 1303.12 of title 21 of the Code of Federal
Regulations.
Pursuant to sec 1303.23(c) of title 21 of the Code of Federal
Regulations, the Deputy Administrator of the DEA will, in early
1996, adjust aggregate production quotas and individual manufacturing
quotas allocated for the year based upon 1995 year-end inventory
and actual 1995 disposition data supplied by quota recipients
for each basic class of Schedule I or II controlled substance.
Therefore, under the authority vested in the Attorney General
by section 306 of the Controlled Substances Act of 1970 (21
U.S.C. 826), delegated to the Administrator of the DEA by sec
0.100 of title 28 of the Code of Federal Regulations, and redelegated
to the Deputy Administrator pursuant to sec 0.104 of title 28
of the Code of Federal Regulations, the Deputy Administrator
hereby proposes that the aggregate production quotas for 1996
for the following controlled substances, expressed in grams
of anhydrous acid or base, be established as follows:
--------------------------------------------------------------+---------------
Basic class | Proposed
| 1996 quotas
--------------------------------------------------------------+---------------
|
Schedule I: |
Acetylmethadol.............................................. | 7
Alphacetylmethadol.......................................... | 7
Aminorex.................................................... | 7
Cathinone................................................... | 9
Difenoxin................................................... | 14,000
Dihydromorphine............................................. | 7
2,5-Dimethoxyamphetamine.................................... | 10,650,000
Dimethylamphetamine......................................... | 7
Ethylamine Analog of Phencyclidine.......................... | 5
N-Ethylamphetamine.......................................... | 7
Lysergic acid diethylamide.................................. | 58
Mescaline................................................... | 7
Methaqualone................................................ | 17
Methcathinone............................................... | 9
4-Methoxyamphetamine........................................ | 17
4-Methylaminorex............................................ | 2
3,4-Methylenedioxyamphetamine............................... | 17
3,4-Methylenedioxy-N-ethylamphetamine....................... | 27
3,4-Methylenedioxymethamphetamine........................... | 42
3-Methylfentanyl............................................ | 14
---- page 38577 ----
Normethadone................................................ | 7
Normorphine................................................. | 7
Psilocybin.................................................. | 2
Psilocyn.................................................... | 2
Tetrahydrocannibinols....................................... | 55,100
Schedule II: |
Alfentanil.................................................. | 8,500
Amobarbital................................................. | 15
Amphetamine................................................. | 1,300,100
Cocaine..................................................... | 550,040
Codeine (for sale).......................................... | 58,395,000
Codeine (for conversion).................................... | 16,632,000
Desoxyephedrine, 1,000,000 grams of levodesoxyephedrine for | 1,044,000
use in a noncontrolled, nonprescription product and 44 kg |
for methamphetamine. |
Dextropropoxyphene.......................................... | 118,066,000
Dihydrocodeine.............................................. | 60,000
Diphenoxylate............................................... | 1,063,000
Ecgonine (for conversion)................................... | 650,100
Ethylmorphine............................................... | 12
Fentanyl.................................................... | 120,100
Hydrocodone (for sale)...................................... | 8,880,000
Hydrocodone (for conversion)................................ | 2,800,000
Hydromorphone............................................... | 448,000
Isomethadone................................................ | 12
Levo-alpha-acetylmethadol................................... | 200,000
Levorphanol................................................. | 14,300
Meperidine.................................................. | 10,822,000
Methadone................................................... | 4,551,000
Methadone (for conversion).................................. | 364,000
Methadone Intermediate (for conversion)..................... | 5,534,000
Methamphetamine (for conversion)............................ | 723,000
Methylphenidate............................................. | 10,291,000
Morphine (for sale)......................................... | 12,450,000
Morphine (for conversion)................................... | 76,735,000
Noroxymorphone (for sale)................................... | 2,000
Noroxymorphone (for conversion)............................. | 2,406,000
Opium....................................................... | 1,226,000
Oxycodone (for sale)........................................ | 5,571,000
Oxycodone (for conversion).................................. | 37,300
Oxymorphone................................................. | 11,200
Pentobarbital............................................... | 15,100,000
Phencyclidine............................................... | 40
Phenylacetone (for conversion).............................. | 5,280,000
1-Phenylcyclohexylamine..................................... | 10
1-Piperidinocyclohexanecarbonitrile......................... | 12
Secobarbital................................................ | 400,000
Sufentanil.................................................. | 1,000
Thebaine.................................................... | 9,217,000
--------------------------------------------------------------+---------------
The Deputy Administrator further proposes that aggregate
production quotas for all other Schedules I and II controlled
substances included in secsec 1308.11 and 1308.12 of title 21 of
the Code of Federal Regulations be established at zero.
All interested persons are invited to submit their comments
and objections in writing regarding this proposal. A person
may object to or comment on the proposal relating to any of
the above-mentioned substances without filing comments or objections
regarding the others. If a person believes that one or more
of these issues warrant a hearing, the individual should so
state and summarize the reasons for this belief.
In the event that comments or objections to this proposal
raise one or more issues which the Deputy Administrator finds
warrant a hearing, the Deputy Administrator shall order a public
hearing by notice in the Federal Register, summarizing the issues
to be heard and setting the time for the hearing.
The Office of Management and Budget has determined that notices
of aggregate production quotas are not subject to centralized
review under Executive Order 12866. This action has been analyzed
in accordance with the principles and criteria contained in
Executive Order 12612, and it has been determined that this
matter does not have sufficient federalism implications to warrant
the preparation of a Federalism Assessment.
The Deputy Administrator hereby certifies that this action
will have no significant impact upon small entities whose interests
must be considered under the Regulatory Flexibility Act, 5 U.S.C.
601, et seq. The establishment of annual aggregate production
quotas for Schedules I and II controlled substances is mandated
by law and by international treaty obligations. While aggregate
production quotas are of primary importance to large manufacturers,
their impact upon small entities is neither negative nor beneficial.
Accordingly, the Deputy Administrator has determined that this
action does not require a regulatory flexibility analysis.
Dated: July 19, 1995.
Stephen H. Greene,
Deputy Administrator.
[FR Doc. 95-18407 Filed 7-26-95; 8:45 am]
BILLING CODE 4410-09-M
------------------------------------------------------
The Contents entry for this article reads as follows:
Schedules of controlled substances; production quotas:
Schedules I and II-
1996 proposed aggregate, 38576
</ARTICLE>
.